Posttranslational modifications of proopiomelanocortin in vertebrates and their biological significance
It allows for a more flexible approach to treatment, ensuring that the medication is available even when global supply chains are strained
Qualifying criteria include BMI greater than 27 with prediabetes or established cardiovascular disease, or BMI over 30 with uncontrolled hypertension, advanced kidney disease, or heart failure
The associations with PE and VTE were attenuated and not statistically significant in those without T2D
Among current and previous GLP-1 users, 60.84% said they were concerned about injecting themselves before starting treatment, including 20.89% who said they were very concerned
For many people with obesity or type 2 diabetes, those signals are weak or disrupted